Drugs that contain Tucatinib

1. List of Tukysa drug patents

TUKYSA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7452895 SEAGEN Quinazoline analogs as receptor tyrosine kinase inhibitors
Nov, 2024

(1 year, 5 months from now)

US8648087 SEAGEN N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
Apr, 2031

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9693989 SEAGEN N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
May, 2027

(3 years from now)

US9457093 SEAGEN Solid dispersions of a ERB2 (HER2) inhibitor
Oct, 2032

(9 years from now)

US11504370 SEAGEN NA
Mar, 2033

(9 years from now)

US11207324 SEAGEN Treatment of HER2 positive cancers
Apr, 2038

(14 years from now)

Do you want to check out TUKYSA patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jan 19, 2030
New Chemical Entity Exclusivity (NCE) Apr 17, 2025
New Indication (I) Jan 19, 2026

NCE-1 date: 2024-04-17

Market Authorisation Date: 17 April, 2020

Treatment: Treatment of breast cancer including her2 (erbb2)-positive or -overexpressing breast cancer; Combination treatment of colorectal cancer including ras wild-type her2 (erbb2)-positive or -overexpressing...

Dosage: TABLET;ORAL

More Information on Dosage

TUKYSA family patents

33

United States

11

China

10

Australia

10

Japan

8

European Union

7

Israel

7

Korea, Republic of

7

Russia

6

Canada

6

New Zealand

6

Denmark

6

Spain

6

Portugal

6

Poland

6

Slovenia

5

Cyprus

5

Brazil

4

Ukraine

4

Hong Kong

4

Hungary

4

Taiwan

3

Chile

3

Singapore

3

Norway

3

Mexico

3

South Africa

3

Lithuania

2

Colombia

2

Croatia

2

Malaysia

2

Austria

2

Germany

2

RS

1

Iceland

1

Luxembourg

1

Netherlands

1

Costa Rica

1

ME

1

Philippines

1

Argentina

1

Turkey

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in